Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum β-lactamase AmpC

17Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Escherichia coli isolate MEV, responsible for a bloodstream infection, was resistant to penicillins, cephalosporins, and ertapenem. Molecular and biochemical characterization revealed the production of a novel, chromosome-borne, extended-spectrum AmpC (ESAC) β-lactamase with a Ser-282 duplication and increased carbapenemase activity. This study demonstrates for the first time that chromosome-borne ESAC β-lactamases can contribute to the emergence of ertapenem resistance in E. coli clinical isolates. Copyright © 2011, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Guillon, H., Tande, D., & Mammeri, H. (2011). Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum β-lactamase AmpC. Antimicrobial Agents and Chemotherapy, 55(9), 4443–4446. https://doi.org/10.1128/AAC.01513-10

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free